Related Experiment Video
Updated: Jun 18, 2026
09:37
Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
Published on: August 24, 2018
Metabolic alterations during valproic acid treatment: a prospective study
Ayhan Abaci1, Murat Saygi, Uluc Yis
1Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey.
Pediatric Neurology
|November 26, 2009
Summary
Valproic acid treatment in epileptic children significantly increased body mass index and cholesterol levels, raising concerns for obesity. Regular monitoring for weight gain and metabolic changes is recommended during therapy.
Area of Science:
- Pediatric Endocrinology
- Clinical Neurology
- Metabolic Disorders
Background:
- Epilepsy is a common neurological disorder in children.
- Valproic acid is a widely used antiepileptic drug.
- Potential endocrine and metabolic side effects of valproic acid require investigation.
Purpose of the Study:
- To prospectively evaluate the impact of valproic acid on endocrine and metabolic variables in children with newly diagnosed epilepsy.
- To assess changes in body mass index, glucose metabolism, lipid profiles, and hormone levels during valproic acid treatment.
Main Methods:
- Prospective study involving 30 children with newly diagnosed idiopathic epilepsy.
- Assessment of clinical and laboratory variables at baseline, 6 months, and 12 months of valproic acid treatment.
- Measurements included body mass index, glucose, insulin, lipid profiles, and androgen hormones.
Main Results:
- Significant increases in body mass index and body mass index standard deviation scores were observed during treatment.
- Total and low-density lipoprotein cholesterol levels significantly increased after 12 months.
- A correlation was found between serum valproic acid levels and body mass index at 6 months.
- No significant changes in fasting glucose, insulin, triglycerides, HDL, or androgens in prepubertal children.
Conclusions:
- Valproic acid treatment is associated with weight gain and dyslipidemia in epileptic children.
- Increased risk of overweight and obesity necessitates regular monitoring.
- Further research into the long-term metabolic consequences is warranted.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...